Sanofi (NASDAQ:SNY) Cut to “Hold” at Wall Street Zen

Wall Street Zen lowered shares of Sanofi (NASDAQ:SNY) from a buy rating to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

A number of other brokerages have also issued reports on SNY. Weiss Ratings lowered shares of Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Royal Bank Of Canada assumed coverage on shares of Sanofi in a report on Tuesday, September 8th. They issued a “sector perform” rating for the company. HSBC restated a “buy” rating on shares of Sanofi in a research report on Thursday, September 10th. Finally, Morgan Stanley set a $49.00 price objective on Sanofi in a report on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $49.50.

Sanofi Stock Performance

Sanofi stock opened at $39.51 on Friday. The stock has a 50-day simple moving average of $43.32 and a 200 day simple moving average of $44.12. The stock has a market capitalization of $95.79 billion, a price-to-earnings ratio of 20.69, a P/E/G ratio of 1.20 and a beta of 0.33. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21. Sanofi has a 12-month low of $39.18 and a 12-month high of $52.68.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 30th. The company reported $2.41 EPS for the quarter. The firm had revenue of $13.36 billion for the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The firm’s revenue was up 16.0% compared to the same quarter last year. During the same period in the prior year, the company earned $3.24 EPS. On average, research analysts anticipate that Sanofi will post 5.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. QRG Capital Management Inc. raised its stake in shares of Sanofi by 12.9% during the second quarter. QRG Capital Management Inc. now owns 138,522 shares of the company’s stock worth $5,909,000 after buying an additional 15,800 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its stake in Sanofi by 0.7% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 53,426 shares of the company’s stock valued at $2,279,000 after acquiring an additional 351 shares during the last quarter. Tidal Investments LLC grew its holdings in Sanofi by 21.5% during the 2nd quarter. Tidal Investments LLC now owns 165,289 shares of the company’s stock worth $7,051,000 after acquiring an additional 29,283 shares during the period. Archford Capital Strategies LLC acquired a new stake in Sanofi during the 2nd quarter worth $1,417,000. Finally, WINTON GROUP Ltd bought a new stake in shares of Sanofi during the 2nd quarter valued at $375,000. Institutional investors own 14.03% of the company’s stock.

About Sanofi

Sanofi is a France-based global healthcare company that develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. Its portfolio focuses on areas including immunology, rare diseases, vaccines, diabetes and other chronic conditions, as well as specialized treatments for selected neurological and inflammatory disorders.

The company is known for products such as Dupixent, a biologic used to treat several inflammatory conditions, and a broad range of vaccines marketed through its Sanofi Pasteur business.